Patents by Inventor Parvesh Wadhwani

Parvesh Wadhwani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystal structure of human coronavirus 229E main proteinase and uses for developing SARS inhibitors
    Patent number: 7956078
    Abstract: The invention relates to a method of developing a main proteinase SARS inhibitor. Human coronaviruses are major causes of upper respiratory tract illnesses in humans, in particular, the common cold. Recent investigations have shown that a novel coronavirus causes the Severe Acute Respiratory Syndrome (SARS), a disease that is characterized by high fever, malaise, rigor, headache, non-productive cough or dyspnea, which is rapidly spreading. Within the scope of the invention, based on the structural analysis of the binding mode of the SARS Mpro enzyme, a group of prototype inhibitors is provided that acts as suitable drugs targeting a majority of viral infections of the respiratory tract, including SARS.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: June 7, 2011
    Assignee: Universitat zu Luebeck
    Inventors: Rolf Hilgenfeld, Kanchan Anand, John Ziebuhr, Jeroen R. Mesters, Parvesh Wadhwani
  • Crystal structure of human coronavirus 229E main proteinase and uses for developing SARS inhibitors
    Publication number: 20090137818
    Abstract: The invention relates to a method of developing a main proteinase SARS inhibitor. Human coronaviruses are major causes of upper respiratory tract illnesses in humans, in particular, the common cold. Recent investigations have shown that a novel coronavirus causes the Severe Acute Respiratory Syndrome (SARS), a disease that is characterized by high fever, malaise, rigor, headache, non-productive cough or dyspnea, which is rapidly spreading. Within the scope of the invention, based on the structural analysis of the binding mode of the SARS Mpro enzyme, a group of prototype inhibitors is provided that acts as suitable drugs targeting a majority of viral infections of the respiratory tract, including SARS.
    Type: Application
    Filed: November 10, 2005
    Publication date: May 28, 2009
    Inventors: Rolf Hilgenfeld, Kanchan Anand, John Ziebuhr, Jeroen R. Mesters, Parvesh Wadhwani